



## Clinical trial results:

### Outcome of plasma lipid profile in patients switching from Atripla® to Eviplera® compared to continuing on Atripla® (EfaRiLipidomics)

#### Summary

EudraCT number	2015-002319-13
Trial protocol	ES
Global end of trial date	09 March 2017

#### Results information

Result version number	v1 (current)
This version publication date	04 November 2021
First version publication date	04 November 2021

#### Trial information

##### Trial identification

Sponsor protocol code	EfaRiLipidomics
-----------------------	-----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	VHIR
Sponsor organisation address	Passeig Vall Hebron 119-129, Barcelona, Spain, 08035
Public contact	Joaquin Lopez-Soriano, VHIR, 0034 934894779, joaquin.lopez.soriano@vhir.org
Scientific contact	Servicio Enfermedades Infecciosas, Hospital Vall Hebron, 0034 934893000, mcrespo@vhebron.net

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 March 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	09 March 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To compare the lipidomic profile of patients with HIV -1 viral suppression changing efavirenz + emtricitabine + tenofovir ( Atripla) to rilpivirine + emtricitabine + tenofovir ( Eviplera® ) versus a group of patients who continue to Atripla after 12 weeks from the switch

Protection of trial subjects:

The study was approved by the ethics committee of the Hospital Vall d'Hebron and the Agencia Española del Medicamento y Productos Sanitarios (AEMPS). All participants gave their written informed consent in accordance with the Declaration of Helsinki

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 August 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 29
Worldwide total number of subjects	29
EEA total number of subjects	29

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	29
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study comprised 30 HIV-positive participants aged  $\geq 18$  years on the EFV/FTC/TDF regimen with HIV-RNA < 50 copies/mL for at least 6 months, without other comorbidities. Exclusion criteria included prior virologic failure, any acute or chronic disease that could interfere with the lipidomics analysis, alcohol or other drug abuse.

### Pre-assignment period milestones

Number of subjects started	29
Number of subjects completed	29

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Control group

Arm description:

Patients  $\geq 18$  years old on efavirenz (EFV) co-formulated with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) with HIV-RNA < 50 copies/mL for  $\geq 6$  months continued with EFV/FTC/TDF

Arm type	Active comparator
Investigational medicinal product name	Efavirenz
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pillules
Routes of administration	Oral use

Dosage and administration details:

600 mg daily

<b>Arm title</b>	RPV switch
------------------	------------

Arm description:

Switch from Efavirenz/FTC/TDF to Rilpivirine/FTC/TDF

Arm type	Experimental
Investigational medicinal product name	Rilpivirine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Pillules
Routes of administration	Oral use

Dosage and administration details:

Rilpivirine 25 mg daily

<b>Number of subjects in period 1</b>	Control group	RPV switch
Started	14	15
Completed	14	15

## Baseline characteristics

---

### Reporting groups

Reporting group title	Overall trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	29	29	
Age categorical			
Units: Subjects			
Adults (18-64 years)	29	29	
Gender categorical			
Units: Subjects			
Female	4	4	
Male	25	25	

## End points

### End points reporting groups

Reporting group title	Control group
Reporting group description: Patients ≥ 18 years old on efavirenz (EFV) co-formulated with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) with HIV-RNA < 50 copies/mL for ≥ 6 months continued with EFV/FTC/TDF	
Reporting group title	RPV switch
Reporting group description: Switch from Efavirenz/FTC/TDF to Rilpivirine/FTC/TDF	

### Primary: Total cholesterol

End point title	Total cholesterol
End point description:	
End point type	Primary
End point timeframe: 24 weeks	

End point values	Control group	RPV switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	15		
Units: mg/dL				
arithmetic mean (inter-quartile range (Q1-Q3))	185 (164 to 214)	171 (158 to 195)		

### Statistical analyses

Statistical analysis title	Total Cholesterol
Comparison groups	Control group v RPV switch
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.265
Method	t-test, 1-sided

### Primary: LDL cholesterol

End point title	LDL cholesterol
End point description:	
End point type	Primary

End point timeframe:

24 weeks

End point values	Control group	RPV switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	15		
Units: mg/dL				
arithmetic mean (inter-quartile range (Q1-Q3))	119 (85 to 135)	107 (93 to 130)		

### Statistical analyses

Statistical analysis title	LDL-cholesterol
Comparison groups	Control group v RPV switch
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.585
Method	t-test, 1-sided

### Primary: HDL cholesterol

End point title	HDL cholesterol
End point description:	
End point type	Primary
End point timeframe:	
24 weeks	

End point values	Control group	RPV switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	15		
Units: mg/dL				
arithmetic mean (inter-quartile range (Q1-Q3))	52 (41 to 61)	47 (40 to 49)		

### Statistical analyses

<b>Statistical analysis title</b>	HDL cholesterol
Comparison groups	Control group v RPV switch
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.08
Method	t-test, 1-sided

### Primary: Triglycerides

End point title	Triglycerides
End point description:	
End point type	Primary
End point timeframe:	
24 weeks	

<b>End point values</b>	Control group	RPV switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	15		
Units: mg/dL				
arithmetic mean (inter-quartile range (Q1-Q3))	98 (69 to 160)	105 (84 to 132)		

### Statistical analyses

<b>Statistical analysis title</b>	Triglycerides
Comparison groups	Control group v RPV switch
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.6
Method	t-test, 1-sided

### Primary: Apolipoprotein A

End point title	Apolipoprotein A
End point description:	
End point type	Primary
End point timeframe:	
24 weeks	



<b>End point values</b>	Control group	RPV switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	15		
Units: grams/dL				
arithmetic mean (inter-quartile range (Q1-Q3))	149 (126 to 162)	144 (131 to 150)		

### Statistical analyses

<b>Statistical analysis title</b>	Apo A
Comparison groups	Control group v RPV switch
Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.197
Method	t-test, 1-sided

### Primary: Apolipoprotein B

End point title	Apolipoprotein B
End point description:	
End point type	Primary
End point timeframe:	
24 weeks	

<b>End point values</b>	Control group	RPV switch		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	14	15		
Units: g/dL				
arithmetic mean (inter-quartile range (Q1-Q3))	86 (65 to 90)	78 (68 to 92)		

### Statistical analyses

<b>Statistical analysis title</b>	Apo B
Comparison groups	Control group v RPV switch

Number of subjects included in analysis	29
Analysis specification	Pre-specified
Analysis type	non-inferiority
P-value	= 0.782
Method	t-test, 1-sided

## Adverse events

### Adverse events information<sup>[1]</sup>

Timeframe for reporting adverse events:

24 weeks

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14.1
--------------------	------

### Reporting groups

Reporting group title	Total adverse events
-----------------------	----------------------

Reporting group description: -

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: There were no suspected severe adverse reactions related to the study drugs. Given the study design (two only visits to have lipidomics profiling analyses), no adverse events were reported.

Serious adverse events	Total adverse events		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 29 (3.45%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Infections and infestations			
Dental abscess			
subjects affected / exposed	1 / 29 (3.45%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Total adverse events		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 29 (0.00%)		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The small number of patients included, together with the risk of confounding variables, are important limitations of the study. The included patients were on stable ART with EFV/FTC/TDF for more than 6 years. This could result in selection bias.
---

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/32344934>